Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | C1R | P00736 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25430635 | 0.83 | HSD17B10 (0.51) | HSD17B10EPHX2TRPV1 | |
| SCHEMBL25428669 | 0.83 | HSD17B10 (0.47) | HSD17B10EPHX2TP53MAPTAKR1C3 | |
| SCHEMBL25430373 | 0.83 | EPHX2 (0.44) | EPHX2TP53MAPTAKR1C3TRPV1 | |
| SCHEMBL25430647 | 0.78 | HSD17B10 (0.55) | HSD17B10EPHX2MAPTTRPV1ALDH1A1 | |
| SCHEMBL25429720 | 0.78 | HSD17B10 (0.55) | HSD17B10EPHX2TRPV1ALDH1A1 | |
| SCHEMBL25429357 | 0.76 | TP53 (0.42) | EPHX2TP53MAPTAKR1C3TRPV1 | |
| SCHEMBL9400251 | 0.73 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1 | |
| SCHEMBL25429394 | 0.73 | HSD17B10 (0.52) | HSD17B10TRPV1 | |
| SCHEMBL25431622 | 0.72 | HSD17B10 (0.51) | HSD17B10EPHX2MAPTTRPV1ALDH1A1 | |
| SCHEMBL16481432 | 0.72 | KIF11 (0.52) | TP53MAPTAKR1C3ALDH1A1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |